| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 4054 | 2013 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3578 | 2014 |
| Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ... New England Journal of Medicine 376 (22), 2109-2121, 2017 | 2222 | 2017 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1709 | 2017 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1186 | 2017 |
| Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer MG Krebs, R Sloane, L Priest, L Lancashire, JM Hou, A Greystoke, ... Journal of clinical oncology 29 (12), 1556-1563, 2011 | 1051 | 2011 |
| Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer JM Hou, MG Krebs, L Lancashire, R Sloane, A Backen, RK Swain, ... Journal of Clinical Oncology 30 (5), 525-532, 2012 | 978 | 2012 |
| Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer CL Hodgkinson, CJ Morrow, Y Li, RL Metcalf, DG Rothwell, F Trapani, ... Nature medicine 20 (8), 897-903, 2014 | 795 | 2014 |
| Molecular analysis of circulating tumour cells—biology and biomarkers MG Krebs, RL Metcalf, L Carter, G Brady, FH Blackhall, C Dive Nature reviews Clinical oncology 11 (3), 129-144, 2014 | 691 | 2014 |
| Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component JCH Yang, MJ Ahn, DW Kim, SS Ramalingam, LV Sequist, WC Su, ... Journal of Clinical Oncology 35 (12), 1288-1296, 2017 | 585 | 2017 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 545 | 2018 |
| Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches MG Krebs, JM Hou, R Sloane, L Lancashire, L Priest, D Nonaka, TH Ward, ... Journal of thoracic oncology 7 (2), 306-315, 2012 | 545 | 2012 |
| Circulating tumor cells as a window on metastasis biology in lung cancer JM Hou, M Krebs, T Ward, R Sloane, L Priest, A Hughes, G Clack, ... The American journal of pathology 178 (3), 989-996, 2011 | 520 | 2011 |
| Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial C Faivre-Finn, M Snee, L Ashcroft, W Appel, F Barlesi, A Bhatnagar, ... The Lancet Oncology 18 (8), 1116-1125, 2017 | 511 | 2017 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 419 | 2017 |
| Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report RS Irwin, CL French, AB Chang, KW Altman, TM Adams, E Azoulay, ... Chest 153 (1), 196-209, 2018 | 415 | 2018 |
| Treatment of unexplained chronic cough: CHEST guideline and expert panel report P Gibson, G Wang, L McGarvey, AE Vertigan, KW Altman, SS Birring, ... Chest 149 (1), 27-44, 2016 | 389 | 2016 |
| Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer BJ Solomon, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... Journal of Clinical Oncology 36 (22), 2251-2258, 2018 | 381 | 2018 |
| Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer R Polański, CL Hodgkinson, A Fusi, D Nonaka, L Priest, P Kelly, F Trapani, ... Clinical Cancer Research 20 (4), 926-937, 2014 | 349 | 2014 |
| Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non–small cell lung cancer: the SELECT-1 randomized … PA Jänne, MM van den Heuvel, F Barlesi, M Cobo, J Mazieres, L Crinò, ... Jama 317 (18), 1844-1853, 2017 | 341 | 2017 |
